# NCIC Clinical Trials Group Policy for Investigator Credentialing CTG-POL-0011 v0007 (2013Apr07)



# NCIC CTG Policy for Investigator Credentialing

 This policy establishes guidelines and procedures for determining investigator credentials and requirements for participation as an investigator on NCIC Clinical Trials Group (CTG) clinical trials.

### **Investigator Registration**

- Investigators interested in becoming members register with NCIC CTG as an investigator and <u>annually</u> renew their registration.
- Registration requires submission of a current CV and Investigator Registration Form



### **Investigator Type**

- Investigator category determining qualifications for trial participation as:
  - Qualified Investigator (QI)
  - Sub-Investigator (SI)
- Trial-related duties may be limited depending on Trial Complexity Level and Investigator Type



### **Investigator Type**

**Type 1:** Medical doctor with institutional privileges to independently provide care to cancer patients (e.g. Medical Oncologist)

Type 2: Medical doctors providing care to cancer patients in a limited/supervised setting (e.g. Fellow, GPO)

Type 3: Health care professional providing care to cancer patients in a limited/supervised setting (e.g. ACNP, Physician Assistant)



### **Trial Complexity Level**

- Level 1: High Risk and Complexity
  - Requires sub-specialization in oncology including experience evaluating highly complex interventions
- Level 2: Standard Risk and Complexity
  - Testing oncologic-directed medical interventions
    (e.g. a drug, radiation therapy, surgical technique)
- Level 3: Low Risk and Complexity
  - Testing common standards of care and/or interventions that do not require specialized oncology certification



# NCIC CTG Investigator Roles by Trial Risk & Complexity

Trial Risk Level	Investigator Type					
	TYPE 1	TYPE 2	TYPE 3			
LEVEL 1	QI/SI	SI*	SI*			
LEVEL 2	QI/SI	QI/SI	SI*			
LEVEL 3	QI/SI	QI/SI	QI/SI			

<sup>\*</sup> Delegation of duties 'Confirm Eligibility' and 'Trial-Related Medical Decisions ' are not permitted. Not permitted to be the enrolling investigator on NCIC CTG trials



# Participants List & Qualified Investigator Delegation of Duties CTG-REF-0023 v0003 (2014Feb17)

### **Participants List**

- List of qualified CTP at centre for a trial; required prior to centre local activation and for all additions and removals of CTP
- PL requirements include:
  - Full name of CTP
  - Designated trial role (may have ≥1 role)
  - New role PTECH (optional)
  - Delegated duties (each CTP must have ≥1 duty)
  - Start (and stop) dates for participation
  - QI approval of all CTPs
  - Essential/mandatory roles QI, PCRA, ECRA, PPHARM (trials with investigational agents)



#### **Delegated Duties**

- QI should maintain a list of appropriately qualified person to whom they have delegated significant trial-related duties
  - QI & SI (Type 1): All duties permitted
  - SI (Type 2 & 3): Duties are dependent on Trial Complexity Level
  - CRAs: Specified duties based on CRA role
  - PHARM/PTECH: Study Drug Management



### Permissible Delegations by Role

#	Term	QI	SI	PCRA ACRA		PPHARM PHARM PTECH
1	Confirm Subject Eligibility	$\overline{\checkmark}$	<b>1</b>			
2	Informed Consent	$\overline{\checkmark}$	V	$\overline{\checkmark}$		
	Trial-Related Medical Decisions	$\overline{\checkmark}$	<b>1</b>			
6	Request/Coordinate Unblinding	$\overline{\checkmark}$	$\overline{\mathbf{V}}$			
10	IRB/REB Communication	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\mathbf{V}}$	
	Pre-Trial Subject Screening	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\checkmark}$		
14	Processing Subject Enrolment	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\checkmark}$		
15	Accountability of Investigational Agent(s)	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\checkmark}$		$\overline{\checkmark}$
16	Dispensing of Investigational Agent(s)	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\checkmark}$		$\overline{\checkmark}$
17	Administration of Investigational Agent(s)	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\checkmark}$		
19	Perform Trial Medical Assessments	$\overline{\checkmark}$	$\overline{\checkmark}$			
20	Perform Other Assessments	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\checkmark}$		
21	Data Management	$\overline{\checkmark}$	$\overline{\checkmark}$	$\overline{\checkmark}$		
22	Biologic Sample Management	$\overline{\checkmark}$	V	$\overline{\checkmark}$		
23	Document Adverse Events	$\overline{\checkmark}$	V	$\overline{\checkmark}$		

NCIC CTG 1Level 1 Trial must be Type 1 Investigator; Level 2 Trials must be Type 1 or Type 2 NCIC GEC Investigator

### **Mapping Investigator Roles**

Previous Term	New Term			
Principal Investigator (PI) →	Qualified Investigator (QI)			
Additional Investigator (AI)→	Sub Investigator (SI)			
Clinical Investigator (CI) →	Sub Investigator (SI)			

## **Mapping Delegated Duties**

Retired Duties		
#	Term	
4	Evaluation of Trial Lab Results	
	[Incorporated into Duty 19]	
5	Assess Adverse Events	
	[Incorporated into Duty 19]	
9	Perform Physical Exams	
	[Incorporated into Duty 19/20]	
12	CRF Completion/Corrections	
	[Incorporated into Duty 21]	
13	Query Resolution	
	[Incorporated into Duty 21]	
18	Other: Specify	
	[Incorporated into Duty Other]	